Oyster Point Pharma Inc
NASDAQ:OYST
Intrinsic Value
Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of OYST.
Oyster Point Pharma Inc's market capitalization is 299.7m USD.
OYST stock price is 11.17 USD.
OYST.
OYST. Open DCF Valuation
OYST. Open Relative Valuation
OYST.
OYST's Revenue has grown by 9% over the past 12 months.
OYST has positive Net Debt. This means that the company has more debt (92m USD) than cash and short-term investments (69m USD).
OYST's long-term liabilties (131m USD) exceed its long-term assets (109m USD).
OYST has positive Gross Profit for the last twelve months.
OYST's ROE (Return on Equity) has significantly decreased in the last 3 years from -50% to -306%, and is approaching profitability.
OYST's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 10 424% to -727%.
OYST has negative Operating Income for the last twelve months.
OYST has negative Net Income for the last twelve months.
OYST's ROE (Return on Equity) for the past 12 months is negative and is equal to -306%.
OYST's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -727%.
OYST's Revenue is forecast to grow at a rate of 98% per year over the next 3 years.
OYST has negative Free Cash Flow for the last twelve months.
OYST's short-term assets (98m USD) exceed its short-term liabilties (29m USD).
OYST has negative three-year average ROE (Return on Equity): -65%. The company is not efficient at transforming stockholders' equity into net income.
OYST has negative three-year average ROIC (Return on Invested Capital): -1 297%. The company is not efficient at using invested capital to generate operating income.
OYST's D/E (Debt to Equity) is very low and is equal to -4.15.
OYST's Altman Z-Score is very low and is equal to -8.92.
OYST doesn't generate enough operating income (-158m USD) to safely cover interest payments on its debt (7m USD).
Fundamental Analysis
Oyster Point Pharma Inc
Balance Sheet Decomposition
Oyster Point Pharma Inc
| Current Assets | 97.7m |
| Cash & Short-Term Investments | 68.8m |
| Receivables | 13.2m |
| Other Current Assets | 15.7m |
| Non-Current Assets | 11.5m |
| Long-Term Investments | 886k |
| PP&E | 4.9m |
| Other Non-Current Assets | 5.7m |
| Current Liabilities | 29.2m |
| Accounts Payable | 4.1m |
| Accrued Liabilities | 25m |
| Other Current Liabilities | 17k |
| Non-Current Liabilities | 102.2m |
| Long-Term Debt | 92.2m |
| Other Non-Current Liabilities | 10m |
Earnings Waterfall
Oyster Point Pharma Inc
|
Revenue
|
19.6m
USD
|
|
Cost of Revenue
|
-4.5m
USD
|
|
Gross Profit
|
15.1m
USD
|
|
Operating Expenses
|
-173.5m
USD
|
|
Operating Income
|
-158.5m
USD
|
|
Other Expenses
|
-18.2m
USD
|
|
Net Income
|
-176.6m
USD
|
Free Cash Flow Analysis
Oyster Point Pharma Inc
What is Free Cash Flow?
OYST Profitability Score
Profitability Due Diligence
Oyster Point Pharma Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Oyster Point Pharma Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
OYST Solvency Score
Solvency Due Diligence
Oyster Point Pharma Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Oyster Point Pharma Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OYST Price Targets Summary
Oyster Point Pharma Inc
Ownership
OYST Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
OYST Price
Oyster Point Pharma Inc
| Average Annual Return | -0.31% |
| Standard Deviation of Annual Returns | 23.38% |
| Max Drawdown | -91% |
| Market Capitalization | 299.7m USD |
| Shares Outstanding | 26 844 300 |
| Percentage of Shares Shorted | 2.04% |
OYST News
Last Important Events
Oyster Point Pharma Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Oyster Point Pharma Inc
Company Profile
Oyster Point Pharma Inc
Country
Industry
Market Cap
Dividend Yield
Description
Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The company is headquartered in Princeton, New Jersey and currently employs 303 full-time employees. The company went IPO on 2019-10-31. The firm is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ophthalmic diseases. The firm's lead product candidate is TYRVAYA Nasal Spray, a nicotinic acetylcholine receptor (nAChR) agonist for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the trigeminal parasympathetic pathway (TPP) and stimulating the glands and cells responsible for natural tear film production. The company is sprayed into the anterior portion of the nasal cavity and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.
You don't have any saved screeners yet
